<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03521245</url>
  </required_header>
  <id_info>
    <org_study_id>OB0012018</org_study_id>
    <nct_id>NCT03521245</nct_id>
  </id_info>
  <brief_title>Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer</brief_title>
  <official_title>Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Omicsway Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oncobox Ltd., Russia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vitamed, Russia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Republican Oncological Dispensary of Karelia Republic, Russia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Omicsway Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to identify molecular markers at the level of molecular pathway
      activation to predict efficacy of anti-HER2 therapy with Trastuzumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Biopsy and/or surgical samples from Her2-positive breast cancer patients treated with
      Trastuzumab alone or in combinations with other regimens of chemotherapy with known clinical
      outcomes will be collected and subjected to mRNA sequencing. Expression profiles will be
      analysed using original bioinformatic platform OncoBox. Based on comparison of molecular
      pathways activation strength and clinical response to Trastuzumab and chemotherapy, this
      study aims to identify molecular markers predicting efficacy of therapy with Trastuzumab and
      the possibility of further relapse.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">April 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response by RECIST v1.1 or pathological response according to Chevallier system</measure>
    <time_frame>1 year</time_frame>
    <description>Tumor response by RECIST v1.1 or pathological response according to Chevallier system</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>HER2-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Trastuzumab monotherapy</arm_group_label>
    <description>Her2-positive breast cancer patients treated with Trastuzumab (monotherapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy plus Trastuzumab</arm_group_label>
    <description>Her2-positive breast cancer patients treated with Trastuzumab in combination with other regimens of chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>RNA sequencing</intervention_name>
    <description>Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.</description>
    <arm_group_label>Trastuzumab monotherapy</arm_group_label>
    <arm_group_label>Chemotherapy plus Trastuzumab</arm_group_label>
    <other_name>RNA-seq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transcriptome analysis</intervention_name>
    <description>Analysis of RNA-seq data using the Oncobox algorithm.</description>
    <arm_group_label>Trastuzumab monotherapy</arm_group_label>
    <arm_group_label>Chemotherapy plus Trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Standard Trastuzumab treatment regimen recommended for breast cancer</description>
    <arm_group_label>Trastuzumab monotherapy</arm_group_label>
    <arm_group_label>Chemotherapy plus Trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Standard chemotherapy regimen recommended for breast cancer</description>
    <arm_group_label>Chemotherapy plus Trastuzumab</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Formalin-fixed, paraffin embedded pathological samples of breast cancer obtained during
      radical mastectomy or core needle biopsy
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Residents of North-Western and Central Parts of Russian Federation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult females

          -  histologically confirmed HER2-positive breast cancer

          -  available FFPE samples of breast cancer tissue

          -  patients treated with Trastuzumab alone or in combination(s) with other regimens of
             chemotherapy with known outcome according to RECIST 1.1

          -  stage II or more

          -  patients who have signed an informed consent

        Exclusion Criteria:

          -  less than 70% of intact tumor cells in available FFPE samples
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Anton A Buzdin, Ph.D., D.Sc</last_name>
    <phone>+18883822725</phone>
    <email>buzdin@oncobox.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria V Suntsova, MS</last_name>
    <phone>+79261076626</phone>
    <email>suntsova@oncobox.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OmixWay Corporation</name>
      <address>
        <city>Walnut</city>
        <state>California</state>
        <zip>91789</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anton A Buzdin, Ph.D., D.Sc</last_name>
      <phone>888-382-2725</phone>
      <email>buzdin@oncobox.com</email>
    </contact>
    <contact_backup>
      <last_name>Maria V Suntsova, MS</last_name>
      <phone>+79261076626</phone>
      <email>suntsova@oncobox.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Republican Oncological Dispensary of the Ministry of Healthcare of Karelia Republic</name>
      <address>
        <city>Petrozavodsk</city>
        <state>Karelia Republic</state>
        <zip>185007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirill S Ignatyev, MD</last_name>
      <phone>+79535323105</phone>
      <email>kirillignatev@bk.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vitamed</name>
      <address>
        <city>Moscow</city>
        <zip>121309</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena V Poddubskaya, MD</last_name>
      <phone>+79857695758</phone>
      <email>podd-elena@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>&quot;Oncobox&quot; Ltd.</name>
      <address>
        <city>Moscow</city>
        <zip>143026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maksim Sorokin, PhD</last_name>
      <phone>+79167991191</phone>
      <email>sorokin@oncobox.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2018</study_first_submitted>
  <study_first_submitted_qc>April 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2018</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Omicsway Corporation</investigator_affiliation>
    <investigator_full_name>Anton A. Buzdin</investigator_full_name>
    <investigator_title>Chief Scientific Officer</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>epidermal growth factor receptor</keyword>
  <keyword>HER2</keyword>
  <keyword>EGFR</keyword>
  <keyword>biomarkers</keyword>
  <keyword>targeted therapy</keyword>
  <keyword>NGS</keyword>
  <keyword>RNAseq</keyword>
  <keyword>mRNA</keyword>
  <keyword>transcriptome analysis</keyword>
  <keyword>signaling pathway</keyword>
  <keyword>intracellular molecular pathway</keyword>
  <keyword>OncoBox</keyword>
  <keyword>trastuzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Study Protocol Statistical Analysis Plan (SAP) NGS data Clinical Study Report (CSR)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

